Using human umbilical cord mesenchymal stem cells combined with allogenic platelet-rich fibrin membrane for the treatment of dual limb ischemia in an elderly patient: A case report. Issue 10 (12th March 2021)

• Record Type: Journal Article
• Authors: Ju, Wendong; Fu, Simao; Huang, Jun; Li, Bishuang; Wang, Li; Zheng, Minmin; Song, Haojie; Li, Quanyong; Zhou, Qiaoyun; He, Meixing
• Other Names: Saranathan. Maya section editor.
• Is Part Of: Medicine. Volume 100:Issue 10(2021)
• Publication Date: 2021-03-12
• Subjects: atherosclerosis -- lower limb ischemia -- mesenchymal stem cells -- platelet-rich fibrin; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000025068
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: To describe the clinical effects of human umbilical cord mesenchymal stem cells (UCMSCs) combined with allogenic platelet-rich fibrin (PRF) for the treatment of lower limb ischemia in an elderly patient. Patient concerns: The patient was a 93-year-old Chinese woman with bilateral foot gangrene and ulcers lasting for 6 months. She had a prior history of Behcet's disease. Diagnoses: The admitting diagnosis for this episode was atherosclerosis bilateral limb ischemia. Interventions: First, treatment consisting of immunosuppressants, anticoagulation, antiplatelets, and anti-microbials were instituted. A UCMSC suspension was administered intravenously and injected into the lower limbs twice. An allogenic PRF membrane was externally applied 15 times over the lower limbs. Outcomes: The patient's pain improved and the 6 ulcers healed. Lessons: The combination of UCMSCs with a PRF membrane for the treatment of lower limb ischemia in an elderly patient is effective and safe. More and larger trials are needed before incorporating this therapy into mainstream treatment.